Stock Market Performance
- Opening Price: $329.48
- Closing Price: $331.70 (increase of $2.61, approximately 0.79% from previous close of $329.09)
- Intraday High: $332.33
- Intraday Low: $328.00
- Trading Volume: Approximately 5.83 million shares, indicating robust trading activity relative to average volume
Market Context
On May 8, 2026, the broader market showed modest gains across major indices. The S&P 500 increased by about 0.2%, the Dow Jones Industrial Average gained approximately 0.4%, and the Nasdaq Composite rose roughly 0.6%. This general positive market sentiment likely contributed to the upward movement in Amgen’s stock as investors exhibited increased risk appetite.
Key News and Events
1. Earnings Report
Amgen released its first-quarter 2026 financial results, which had a significant impact on the stock price. The company reported earnings per share (EPS) of $5.15, surpassing analyst expectations of $4.73. This earnings surprise contributed to strengthening investor confidence and helped drive the stock price higher.
Sales Growth: Sales of Amgen’s Repatha® (evolocumab) increased by 34% year-over-year to $876 million, supported by a 35% growth in volume. This strong sales performance highlights the robust demand for the company’s products and effective market execution.
2. Analyst Upgrades
Following the earnings announcement, several analysts revised their price targets and ratings for Amgen. For example, Erste Group Bank upgraded its earnings per share estimates for fiscal year 2026. These analyst upgrades positively influenced market sentiment around the stock.
3. Investment Announcements
Amgen disclosed a $300 million investment in U.S. manufacturing, raising its total investment to nearly $2 billion over the past year. This initiative aims to bolster American manufacturing capacity and improve supply chain resilience. The announcement was perceived favorably by investors as it underscores the company’s commitment to long-term operational strength.
4. Market Analysts' Commentary
Market analysts expressed optimism toward Amgen’s growth potential, emphasizing its strong product pipeline and strategic investments. The company’s ability to exceed earnings expectations and its focus on expanding manufacturing capabilities were identified as key factors that could support future growth.
Conclusion
On May 8, 2026, Amgen Inc. exhibited a positive trading day, closing at $331.70 after opening at $329.48. The stock traded within a range of $328.00 to $332.33 on a volume of approximately 5.83 million shares. The day’s performance was primarily driven by the company’s strong first-quarter earnings report, analyst upgrades, and significant manufacturing investment announcements. These company-specific developments, combined with a favorable broader market environment, contributed to the stock’s upward trajectory.
Explore more exclusive insights at nextfin.ai.
